Cortisol and 3,4-Methylenedioxymethamphetamine: Neurohormonal Aspects of Bioenergetic Stress in Ecstasy Users

Neuropsychobiology

Volumn 60, Issue 3-4, 2009, Pages 148-158

  Parrott, A C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

3,4 Methylenedioxymethamphetamine; Cognition; Cortisol; Ecstasy; Energy; Hormone; Stress

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; HYDROCORTISONE; NEUROHORMONE; RECREATIONAL DRUG;

BIOENERGY; DEPRESSION; DRUG USE; ENERGY METABOLISM; HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMPULSIVENESS; NERVE CELL LESION; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOBIOLOGY; REVIEW; SOCIAL PSYCHOLOGY; TEMPERATURE STRESS;

ANIMALS; HALLUCINOGENS; HUMANS; HYDROCORTISONE; MODELS, BIOLOGICAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PHYSICAL EXERTION; STRESS, PHYSIOLOGICAL;

EID: 70449461473     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253551     Document Type: Review

References (123)

1. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55: 463-508
2. Ricaurte GA, Bryan G, Strauss L, Seiden LS, Schuster CR: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986-988
3. Ricaurte GA, Yuan J, McCann UD: ( 8 ) 3,4- methylenediox ymethamphet amine (MDMA, 'Ecstasy')-induced serotonin neurotoxicity: Studies in animals. Neuropsychobiology 2000; 42: 5-10
4. Cohen RS: The Love Drug: Marching to the Beat of Ecstasy. New York, Haworth Medical Press, 1998
5. Parrott AC: Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: Cognitive and behavioural indices of change. Neuropsychobiology 2000; 42: 17-24
6. Schifano F: Potential human neurotoxicity of MDMA ('Ecstasy'): Subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000; 42: 25-33
7. Parrott AC: Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002; 71: 837-844
8. Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH: Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol 2006; 20: 456-463
9. Suy K, Gijsenbergh F, Baute L: Emergency medical assistance during a mass gathering. Eur J Emerg Med 1999; 6: 249-254
10. Huether G, Zhou D, Ryuther E: Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4 methylenediox ymethamphet amine (MDMA, 'ecstasy') and its congeners. J Neural Transm 1997; 104: 771-794
11. Malberg JE, Seiden LS: Small changes in ambient temperature cause large changes in 3,4- methylenediox ymethamphet amine (MDMA)- induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998; 18: 5086-5094
12. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR: Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol 2004; 18: 412-416
13. Cowan RL: Neuroimaging research in human MDMA users: A review. Psychopharmacology 2007; 189: 539-556
14. Eastern N, Marsden CA: Ecstasy: Are animal data consistent between species and can they translate to humans? J Psychopharmacol 2006; 20: 194-210
15. Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ: Neuroimaging findings with MDMA/ecstasy: Technical aspects, conceptual issues and future prospects. J Psychopharmacol 2006; 20: 164-175
16. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A: Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 2003; 167: 85-96.
17. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A: Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: The longitudinal perspective. J Psychopharmacol 2006; 20: 211-225
18. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR: Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992; 18: 331-341
19. Fox H, Parrott AC, Turner JJD: Ecstasy/ MDMA-related cognitive deficits: A function of dosage rather than awareness of problems. J Psychopharmacol 2001; 15: 273-281
20. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H: Impaired cognitive performance in drug-free recreational ecstasy (MDMA) users. J Neurol Neurosurg Psychiatry 2000; 68: 719-725
21. Morgan MJ: Memory deficits associated with recreational use of 'ecstasy' (MDMA). Psychopharmacology 1999; 141: 30-36
22. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K: Cognitive performance in recreational users of MDMA or 'ecstasy': Evidence for memory deficits. J Psychopharmacol 1998; 12: 79-83
23. Parrott AC, Buchanan T, Scholey AB, Heffernan TM, Ling J, Rodgers J: Ecstasy-attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002; 17: 309-312
24. Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 1998; 139: 261-268
25. Rodgers J: Cognitive performance amongst recreational users of 'ecstasy'. Psychopharmacology 2000; 151: 19-24
26. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC: Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: A web-based study. J Psychopharmacol 2003; 17: 379-386
27. Verkes RJ, Gigsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M: Cognitive performance and serotonergic function in users of Ecstasy. Psychopharmacology 2001; 53: 196-202
28. Reay JL, Hamilton C, Kennedy DO, Scholey AB: MDMA polydrug users show processspecific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharmacol 2006; 20: 385-388
29. Wareing M, Fisk M, Murphy JE: Working deficits in current and previous users of MDMA ('ecstasy'). Br J Psychol 2000; 91: 181-188
30. Wareing M, Murphy PN, Fisk JE: Visuospatial memory impairments in users of MDMA ('ecstasy'). Psychopharmacology 2004; 173: 391-397 (Pubitemid 38703813)
31. Zakzanis KK, Young DA: Memory impairment in abstinent MDMA ('ecstasy') users: A longitudinal investigation. Neurology 2001; 56: 966-969
32. Zakzanis KK, Campbell Z: Memory impairment in now abstinent MDMA users and continued users: A longitudinal follow-up. Neurology 2006; 66: 740-741
33. Fisk JE, Montgomery C, Wareing M, Murphy PN: Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology 2005; 181: 550-559 (Pubitemid 41480904)
34. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ: Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('ecstasy') polydrug users. Psychopharmacology 2002; 162: 203-214
35. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D: Residual effects of illicit 3,4-methylenedioxymethamphetamine in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004; 75: 135-147
36. MacInnes N, Handley SL, Harding GFA: Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 2001; 15: 181-186
37. McCann UD, Eligulashvili V, Ricaurte GA: 3,4-MDMA ('Ecstasy')-induced serotonin neurotoxicity: Clinical studies. Neuropsychobiology 2000; 42: 11-16
38. McCann UD, Ricaurte GA: Effects of (+/-) 3,4- methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. Sci World J 2007; 2: 231-238
39. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C: Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 2004; 173: 434-439
40. Milani RM, Parrott AC, Schifano F, Turner JJ: Pattern of cannabis use in ecstasy polydrug users: Moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum Psychopharmacol 2005; 20: 240-261
41. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R: Immunomodulating properties of MDMA alone and in combination with alcohol: A pilot study. Life Sci 1999; 65: 309-316
42. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Pujadas M, Bacosi A, Menoyo E, Segura J, de la Torre R: Effects of repeated doses of MDMA ('ecstasy') on cell-mediated immune response in humans. Life Sci 2001; 69: 2931-2941
43. Parrott AC, Milani R, Parmar R, Turner JJD: Ecstasy polydrug users and other recreational drug users in Britain and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology 2001; 159: 77-82
44. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB: Dancing hot on ecstasy: Physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users. Hum Psychopharmacol 2006; 21: 285-298
45. Quednow BB, Kuhn KU, Hoenig K, Maier W, Wagner M: Prepulse inhibition and habituation of acoustic startle response in male MDMA ('Ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 2004; 29: 982-990
46. Roiser JP, Sahakian BJ: Relationship between ecstasy use and depression: A study controlling for poly-drug use. Psychopharmacology 2004; 173: 411-417
47. Soar K, Turner JJD, Parrott AC: Psychiatric disorders in recreational Ecstasy (MDMA) users: A literature review focusing upon personal predisposition factors and drug histories. Hum Psychopharmacol 2001; 16: 641-646
48. Soar K, Parrott AC, Turner JJD: Persistent neuropsychological problems after seven years of abstinence from recreational Ecstasy (MDMA): A case study. Psychol Rep 2004; 95: 192-196
49. Soar K, Parrott AC, Turner JJD: No more the 'love drug': Sexual behaviour impairments in Ecstasy users. J Psychopharmacol 2005; 19: A25
50. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105-115
51. Turner JJD, Nicolas L, Parrott AC: Reduced calorie intake in the week following weekend MDMA (ecstasy) use. J Psychopharmacol 1998; 12:a43
52. Zhou JF, Chen P, Zhou YH, Zhang L, Chen HH: 3,4- methylenedioxymethamphetamine abuse may cause oxidative stress and potential free radical damage. Free Radic Res 2003; 37: 491-497
53. Parrott AC: MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J Psychopharmacol 2006; 20: 147-163
54. Back-Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE: Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin Neuropsychol 2003; 17: 446-459
55. Jansen KLR: Ecstasy (MDMA) dependence. Drug Alcohol Depend 1999; 53: 121-124
56. Schilt T, de Win MM, Koeter M, Jager G, Korf DJ, van den Brink W, Schmand B: Cognition in novice ecstasy users with minimal exposure to other drugs: A prospective cohort study. Arch Gen Psychiatry 2007; 64: 728-736.
57. Mejias S, Rossignol M, Debatisse D, Streel E, Servais L, Guerit JM, Philippot P, Campanella S: Event-related potentials in ecstasy (MDMA) users during a visual oddball task. Biol Psychol 2005; 69: 333-352
58. Parrott AC, Sisk E, Turner J: Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 2000; 60: 105-110
59. Schifano F, DiFuria L, Forza G, Minicuci N, Bricolo R: MDMA consumption in the context of polydrug abuse: A report on 150 patients. Drug Alc Depend 1998; 52: 85-90
60. Clemens KJ, McGregor IS, Hunt GE, Cornish JL: MDMA, methamphetamine and their combination: Possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev 2007; 26: 9-15
61. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH: Electrophysiological evidence of serotonergic impairment in long-term MDMA ('Ecstasy') users. Am J Psychiatry 2001; 158: 1687-1692
62. Morgan MJ, McFie L, Fleetwood LH, Robinson JA: Ecstasy (MDMA): Are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 2002; 159: 294-303
63. Parrott A, Morinan A, Moss M, Scholey A: Understanding Drugs and Behaviour. Chichester, Wiley, 2004
64. Parrott AC, Lock J, Conner AC, Kissling C, Thome J: Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: Prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008; 57: 165-180
65. Ramaekers JG, Kuypers KP: Acute effects of 3,4- methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: Alone and in combination with alcohol. Neuropsychopharmacology 2006; 31: 1048-1055
66. Rodgers J, Buchanan T, Pearson C, Parrott AC, Ling J, Hefferman TM, Scholey AB: Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study. J Psychopharmacol 2006; 20: 437-446
67. Sala M, Braida D: Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacol Biochem Behav 2005; 81: 407-416
68. Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J: Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/ MDMA users: A www study. Addict Behav 2004; 29: 743-752
69. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J: Cannabis and Ecstasy/ MDMA (3,4-methylenedioxymethamphetamine): An analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 2007a;114: 959-968
70. Rizzo M, Lamers CTJ, Sauer CG, Ramaekers JG, Bechara A, Anderson GJ: Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users. Psychopharmacology 2005; 179: 559-566
71. Parrott AC: MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: The neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004; 50: 329-335
72. Silins E, Copeland J, Dillon P: Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Aust NZ J Psychiatry 2007; 41: 649-655
73. Darvesh AS, Gudelsky GA: Evidence for a role of energy dysregulation in the MDMAinduced depletion of brain 5-HT. Brain Res 2005; 21: 168-175
74. Selye H: The Stress of Life. New York, Mc- Graw Hill, 1956
75. Lovallo WR: Stress and Health: Biological and Psychological Interactions. Thousand Oaks, Sage, 1997
76. Cannon WB: Stresses and strains of homeostasis. Am J Med Sci 1935; 189: 1-14
77. Munck A, Guyre PM, Holbrook NJ: Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984; 5: 25-44
78. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL, Lupien SJ, Roozendaal B, Seckl JR: Do corticosteroids damage the brain? J Neuroendocrinol 2006; 18: 393-411
79. Halberg F: Circadian (about twenty-fourhour) rhythms in experimental medicine. Proc R Soc Med 1963; 56: 253-257
80. Buijs RM, Scheer FA, Kreier F, Yi C, Bos N, Goncharuk VD, Kalsbeek A: Organization of circadian functions: Interaction with the body. Prog Brain Res 2006; 153: 341-360
81. Dumont GJ, Verkes RJ: A review of acute effects of 3,4- methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 2006; 20: 176-187
82. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J: Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136-145
83. De la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J: Pharmacology of MDMA in humans. Ann NY Acad Sci 2000; 914: 225-237
84. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT: Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002; 162: 396-405
85. Parrott AC, Parrott L, Evans A, Kissling C, Thome J: Heavy Ecstasy/MDMA use at cool house parties: Substantial cortisol release and increased body temperature. J Psychopharmacol 2007; 21:a35
86. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R: Serotonergic function after (+/-) 3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans. Int Clin Psychopharmacol 1998; 13: 1-9
87. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F: Long-lasting effects of (+/-)3,4- methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 2000; 47: 127-136
88. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari C, Brambilla F: Hypothalamic- pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy- methamphetamine ('ecstasy') use history: Correlation with dopamine receptor sensitivity. Psychiatry Res 2003; 120: 115-124
89. Nagaraja N, Andrade C, Sudha S, Madan Singh N, Chandra JS, Venkataraman BV: Glucocorticoid mechanisms may contribute to ECT-induced retrograde amnesia. Psychopharmacology 2007; 190: 73-80
90. Backhaus J, Junghanns K, Born J, Hohaus K, Faasch F, Hohagen F: Impaired declarative memory consolidation during sleep in patients with primary insomnia: Influence of sleep architecture and nocturnal cortisol release. Biol Psychiatry 2006; 60: 1324-1330
91. McEwan BS: Sleep deprivation as a neurobiologic and physiologic stressor: Allostasis and allostatic load. Metabolism 2006; 55(suppl 2):S20-S23
92. Wolf OT, Dziobek I, McHugh P, Sweat V, de Leon MJ, Javier E, Convit A: Subjective memory complaints in aging are associated with elevated cortisol levels. Neurobiol Aging 2005; 26: 1357-1363
93. McMorris T, Swain J, Smith M, Corbett J, Delves S, Sale C, Harris RC, Potter J: Heat stress, plasma concentrations of adrenaline, noradrenaline, 5-hydroxytryptamine and cortisol, mood state and cognitive performance. Int J Psychophysiol 2006; 6: 204-215
94. Oei NY, Everaerd WT, Elzinga BM, van Well S, Bermond B: Psychosocial stress impairs working memory at high loads: An association with cortisol levels and memory retrieval. Stress 2006; 9: 133-141
95. Strohle A, Holsboer F: Stress-responsive neurohormones in depression and anxiety. Pharmacopsychiatry 2003; 36(suppl 3):S207-S214
96. Nemeroff CB, Vale WW: The neurobiology of depression: Inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66(suppl 7):5-13
97. Butler GKL, Montgomery AMJ: Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. Drug Alcohol Depend 2004; 76: 55-62.
98. Fishbein DH, Lozovsky D, Jaffe JH: Impulsivity, aggression, and neuroendocrine responses to serotonergic stimulation in substance abusers. Biol Psychiatry 1989; 25: 1049-1066
99. Lovallo WR: Cortisol secretion patterns in addiction and addiction risk. Int J Psychophysiol 2006; 59: 195-202
100. Winstock AR, Griffiths P, Stewart D: Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64: 9-17
101. Davis H, Gass G, Basset J: Serum cortisol response to incremental work in experienced and naive subjects. Psychosom Med 1981; 43: 127-132
102. Hammersley R, Ditton J, Smith I, Short E: Patterns of ecstasy use by drug users. Br J Criminol 1999; 39: 625-647
103. Parrott AC: Chronic tolerance to recreational MDMA (3,4 methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 2005; 19: 71-83
104. Cole JC, Sumnall HR, Smith GW, Rostami- Hodjegan A: Preliminary evidence of the cardiovascular effects of polysubstance misuse in night clubs. J Psychopharmacol 2005; 19: 67-70
105. Liechti ME, Gamma A, Vollenweider FX: Gender differences in the subjective effects of MDMA. Psychopharmacology 2001; 154: 161-168
106. Freedman FR, Johanson C, Tancer ME: Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2005; 183: 248-256
107. Parrott AC, Young L: Increased body temperature in recreational Ecstasy/MDMA users out clubbing and dancing, J Psychopharmacol 2005; 19:a26
108. Davison D, Parrott AC: Ecstasy in recreational users: Self-reported psychological and physiological effects. Hum Psychopharmacol 1997; 12: 91-97
109. Saxbe DE, Repetti RL, Nishina A: Marital satisfaction, recovery from work, and diurnal cortisol among men and women. Health Psychol 2008; 27: 15-25
110. Parrott AC: Human psychopharmacology of Ecstasy (MDMA): A review of fifteen years of empirical research. Hum Psychopharmacol 2001; 16: 557-577
111. Piazza PV, Maccari S, Deminière JM, Le Moal M, Mormède P, Simon H: Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc Natl Acad Sci USA 1991; 88: 2088-2092
112. Chaouloff F: Serotonin, stress and corticoids. J Psychopharmacol 2000; 14: 139-151
113. Goeders NE, Guerin GF: Role of corticosterone in intravenous cocaine self-administration in rats. Neuroendocrinology 1996; 64: 337-348
114. Hargreaves GA, Hunt GE, Cornish JL, Mc- Gregor IS: High ambient temperature increases 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy')-induced Fos expression in a region-specific manner. Neuroscience 2007; 145: 764-774
115. Sousa N, Almeida OF: Corticosteroids: Sculptors of the hippocampal formation. Rev Neurosci 2002; 13: 59-84
116. Greer G, Tolbert R: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18: 319-327
117. Parrott AC: The psychotherapeutic potential of MDMA (3,4- methylenedioxymethamphetamine): An evidence-based review. Psychopharmacology 2007; 191: 181-193
118. McGregor IS, Callaghan PD, Hunt GE: From ultrasocial to antisocial: A role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 2008; 154: 358-368
119. Parrott AC: MDMA and cortisol: neuroendocrine aspects of energetic stress in recreational ecstasy users. J Psychopharmacol 2007; 21:a31
120. Nieuwenhuizen AG, Rutters F: The hypothalamic- pituitary-adrenal-axis in the regulation of energy balance. Physiol Behav 2008; 94: 169-177
121. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH: Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: Possible relationship to neurotoxic effects. Psychopharmacology 2004; 173: 383-390
122. Rendell PG, Gray TJ, Henry JD, Tolan A: Prospective memory impairment in 'ecstasy' (MDMA) users. Psychopharmacology 2007; 194: 497-504
123. Rimmele U, Hediger K, Heinrichs M, Klaver P: Oxytocin makes a face in memory familiar. J Neurosci 2009; 29: 38-42